German China
Novo Nordisk and Inversago Pharma have announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion dollars in cash.  (Source: © Martin Nordmark)
Business Strategy

Novo Nordisk to Takeover Inversago Pharma

Novo Nordisk has plans to acquire Inversago Pharma, a developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders. The 1.075-billion-dollar acquisition includes Inversago Pharma’s lead development asset INV-202, an oral CB1 inverse agonist.

Read on

Providers on the topic

To date, primarily individuals and households are taking measures to adapt to climate change impacts, especially in the Global South. (Source: free licensed)
Global Warming

Around the Globe, Climate Adaptation Lacks Coordination

An extensive meta-study reveals that the world relies too heavily on individual households for climate change adaptation, with little systematic collaboration between global, national, and local actors. Experts from Universität Hamburg and LMU Munich warn of the pressing need for cohesive action, and the potential risks of isolated measures.

Read on
About one in three people get shingles, which causes a painful rash.  (Source: University of Bristol)
Pain Relief

Study on Shingles Requires More Patients

Shingles currently does not have a cure but researchers are looking to find a solution to stop long-term pain from the infection. In this background, doctors and researchers at the universities of Bristol, Oxford, Southampton and Warwick are exploring the idea of consuming amitriptyline tablets to prevent persistent pain.

Read on

Galleries